文献速递神经肿瘤

脑肿瘤患者PET与先进MRI的挑战、局限与陷阱:PET/RANO组报告

Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group.
PubMed 文献 · Neuro Oncol · 2024-01-01

该综述由PET/RANO组撰写,概述胶质瘤或脑转移患者中PET显像与先进MRI技术的潜在挑战、局限与陷阱。尽管存在这些问题,PET与先进MRI在脑肿瘤管理中仍持续发挥不可或缺的作用,通过跨学科协作、标准化方案与持续创新可进一步提升其效用。

要点

  • 放射性氨基酸PET较单独解剖MRI的额外临床价值突出,应支持其广泛临床使用。
  • 灌注MRI等先进MRI技术已由Jumpstarting脑肿瘤药物开发联盟标准化小组提供更新采集方案。
  • 氨基酸PET与灌注MRI等技术存在不足,临床常规中应予以考虑。

核心结论

  • 尽管PET显像与先进MRI技术存在挑战与局限,二者在脑肿瘤管理中仍持续发挥不可或缺的作用。
  • 通过跨学科协作、标准化方案与持续创新来认识和减轻这些挑战,将进一步提升这些模态指导最佳患者治疗的效用。

研究设计与样本

  • 本文为PET/RANO组的综合性综述,概述胶质瘤或脑转移患者中PET显像与先进MRI技术的潜在挑战、局限与陷阱。

主要发现

  • 脑肿瘤诊断已因PET与先进MRI技术的使用而显著演进,这些模态可在鉴别诊断、肿瘤范围勾画、预后判断、肿瘤复发与治疗相关变化的区分及抗癌治疗反应评估等临床应用提供有价值信息。
  • RANO组、欧洲神经肿瘤学会及欧美主要核医学学会的联合推荐强调,放射性氨基酸PET较单独解剖MRI的额外临床价值突出,应支持其广泛临床使用。
  • 针对先进MRI及其在临床实践中持续增加的使用,Jumpstarting脑肿瘤药物开发联盟标准化小组近期为广泛使用的动态磁敏感对比灌注MRI提供了更新采集方案。
  • 除氨基酸PET与灌注MRI外,其他PET示踪剂与先进MRI技术(如MR波谱)具有相当临床意义,并日益整合进日常临床实践。
  • 这些模态存在不足,临床常规中应予以考虑。

临床怎么用

  • RANO组、欧洲神经肿瘤学会及欧美主要核医学学会联合推荐:放射性氨基酸PET较单独解剖MRI的额外临床价值突出,应支持其广泛临床使用。
  • Jumpstarting脑肿瘤药物开发联盟标准化小组提供了广泛使用的动态磁敏感对比灌注MRI的更新采集方案。
  • 作者指出,PET与先进MRI的这些不足应在临床常规中予以考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Brain tumor diagnostics have significantly evolved with the use of positron emission tomography (PET) and advanced magnetic resonance imaging (MRI) techniques. In addition to anatomical MRI, these modalities may provide valuable information for several clinical applications such as differential diagnosis, delineation of tumor extent, prognostication, differentiation between tumor relapse and treatment-related changes, and the evaluation of response to anticancer therapy. In particular, joint recommendations of the Response Assessment in Neuro-Oncology (RANO) Group, the European Association of Neuro-oncology, and major European and American Nuclear Medicine societies highlighted that the additional clinical value of radiolabeled amino acids compared to anatomical MRI alone is outstanding and that its widespread clinical use should be supported. For advanced MRI and its steadily increasing use in clinical practice, the Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition provided more recently an updated acquisition protocol for the widely used dynamic susceptibility contrast perfusion MRI. Besides amino acid PET and perfusion MRI, other PET tracers and advanced MRI techniques (e.g. MR spectroscopy) are of considerable clinical interest and are increasingly integrated into everyday clinical practice. Nevertheless, these modalities have shortcomings which should be considered in clinical routine. This comprehensive review provides an overview of potential challenges, limitations, and pitfalls associated with PET imaging and advanced MRI techniques in patients with gliomas or brain metastases. Despite these issues, PET imaging and advanced MRI techniques continue to play an indispensable role in brain tumor management. Acknowledging and mitigating these challenges through interdisciplinary collaboration, standardized protocols, and continuous innovation will further enhance the utility of these modalities in guiding optimal patient care.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Galldiks N, Kaufmann TJ, Vollmuth P, et al. Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group. Neuro Oncol. 2024. PMID: 38466087. doi:10.1093/neuonc/noae049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。